Insider · CIK 0001706863

RAY DEBANJAN

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001706863

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-01-25	CTMXCytomX Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+90K sh	—	—	90,000
2018-12-12	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.45	+$4,346.7	8,928
2018-12-12	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$15.00	−$45K	5,928
2018-12-12	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	7,220
2018-11-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.45	+$4,346.7	8,928
2018-11-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$15.00	−$45K	5,928
2018-11-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	10,220
2018-10-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.45	+$4,346.7	8,928
2018-10-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$18.46	−$55.4K	5,928
2018-10-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	13,220
2018-09-04	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.45	+$4,346.7	8,928
2018-09-04	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$22.39	−$67.2K	5,928
2018-09-04	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	—	—	16,220
2018-08-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,710 sh	$1.26	+$3,414.329	8,638
2018-08-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+290 sh	$1.45	+$420.181	8,928
2018-08-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$26.05	−$78.2K	5,928
2018-08-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,710 sh	—	—	0
2018-08-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+290 sh	—	—	19,220
2018-07-02	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.26	+$3,779.7	8,928
2018-07-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$22.56	−$67.7K	5,928
2018-07-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	2,710
2018-06-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.26	+$3,779.7	8,928
2018-06-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$25.93	−$77.8K	5,928
2018-06-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	5,710
2018-05-31	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+1,187 sh	$17.90	+$21.2K	5,928
2018-05-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.26	+$3,779.7	7,741
2018-05-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$26.52	−$79.6K	4,741
2018-05-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	8,710
2018-04-02	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$1.26	+$3,779.7	7,741
2018-04-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$28.12	−$84.4K	4,741
2018-04-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	11,710
2018-03-02	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,515 sh	$1.26	+$6,948.349	10,256
2018-03-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,515 sh	$30.06	−$166K	4,741
2018-03-02	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.5K sh	$1.13	+$16.4K	19,226
2018-03-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−12.5K sh	$30.41	−$381K	6,685
2018-03-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,944 sh	$31.02	−$60.3K	4,741
2018-03-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,515 sh	—	—	14,710
2018-03-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.5K sh	—	—	20,000
2018-03-01	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13K sh	$1.26	+$16.4K	17,741
2018-03-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−13K sh	$29.40	−$382K	4,741
2018-03-01	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13K sh	—	—	20,225
2018-02-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,548 sh	$26.69	−$68K	4,741
2018-01-24	CTMXCytomX Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2018-01-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$21.11	−$52.8K	7,289
2017-12-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$20.58	−$51.4K	9,789
2017-11-30	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+163 sh	$12.15	+$1,979.88	12,289
2017-11-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$20.00	−$50K	12,126
2017-10-02	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$18.10	−$45.3K	14,626
2017-09-01	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$17.17	−$42.9K	17,126
2017-08-09	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,500 sh	$15.00	−$37.5K	19,626

Recent filings

Accepted (ET)
Jan 294
RAY DEBANJAN0001567619-19-001863
SEC(opens sec.gov)
Dec 144
RAY DEBANJAN0001567619-18-008005
SEC(opens sec.gov)
Nov 54
RAY DEBANJAN0001567619-18-005082
SEC(opens sec.gov)
Oct 24
RAY DEBANJAN0001567619-18-003477
SEC(opens sec.gov)
Sep 64
RAY DEBANJAN0001567619-18-002232
SEC(opens sec.gov)
Aug 24
RAY DEBANJAN0001140361-18-035277
SEC(opens sec.gov)
Jul 34
RAY DEBANJAN0001140361-18-031328
SEC(opens sec.gov)

Companies

CytomX Therapeutics, Inc.Chief Financial OfficerCTMX

Address

C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400

SOUTH SAN FRANCISCO, CA, 94080